A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

Auteurs

Giuseppe Curigliano, Gilles Romieu, Mario Campone, Thierry Dorval, Lionel Duck, Jean-Luc Canon, Celia Roemer-Becuwe, Mario Roselli, Silvia Neciosup, Wivine Burny, Andrea Callegaro, Pedro Miguel de Sousa Alves, Jamila Louahed, Vincent Brichard, Frédéric F. Lehmann